Identification of Lysosomal and Extralysosomal Globotriaosylceramide (GB3) Accumulations in the Endomyocardial Biopsies Before the Occurrence of Typical Pathological Changes of the Patients with Fabry Disease

Dau-Ming Niu,Ming-Jia Hsu,Fu-Pang Chang,Yung-Hsiu Lu,Sheng-Che Hung,Yu-Chen Wang,Jen-Fan Hang,An-Hang Yang,Han-Rei Lee,Shih-Hsien Sung,Yen-Feng Wang,Wen-Chung Yu,Ting-Rong Hsu,Po-Hsun Huang,Sheng-Kai Chang,Ivan Dzhagalov,Chia-Lin Hsu

DOI: https://doi.org/10.1016/j.ymgme.2017.12.280

IF: 4.204

2018-01-01

Molecular Genetics and Metabolism

Abstract:Lysosomal storage disorders (LSDs) are a vast group of more than 50 clinically identified metabolic diseases. They are singly rare, but they affect collectively 1 on 5,000 live births. They result in most of the cases from an enzymatic defect within lysosomes, which causes the subsequent augmentation of unwanted substrates. This accumulation process leads to plenty of clinical signs, determined by the specific substrate and accumulation area. The majority of LSDs present a broad organ and tissue engagement. Brain, connective tissues, viscera and bones are usually afflicted. Among them, brain disease is markedly frequent (two-thirds of LSDs).The most clinically employed approach to treat LSDs is enzyme replacement therapy (ERT), which is practiced by administering systemically the missed or defective enzyme. It represents a healthful strategy for 11 LSDs at the moment, but it solves the pathology only in the case of Gaucher disease. This approach, in fact, is not efficacious in the case of LSDs that have an effect on the central nervous system (CNS) due to the existence of the blood–brain barrier (BBB). Additionally, ERT suffers from several other weak points, such as low penetration of the exogenously administered enzyme to poorly vascularized areas, the development of immunogenicity and infusion-associated reactions (IARs), and, last but not least, the very high cost and lifelong needed.To ameliorate these weaknesses lot of efforts have been recently spent around the development of innovative nanotechnology-driven ERT strategies. They may boost the power of ERT and minimize adverse reactions by loading enzymes into biodegradable nanomaterials. Enzyme encapsulation into biocompatible liposomes, micelles, and polymeric nanoparticles, for example, can protect enzymatic activity, eliminating immunologic reactions and premature enzyme degradation. It can also permit a controlled release of the payload, ameliorating pharmacokinetics and pharmacodynamics of the drug. Additionally, the potential to functionalize the surface of the nanocarrier with targeting agents (antibodies or peptides), could promote the passage through biological barriers.In this review we examined the clinically applied ERTs, highlighting limitations that do not allow to completely cure the specific LSD. Later, we critically consider the nanotechnology-based ERT strategies that have been in-vitro and/or in-vivo tested to improve ERT efficacy.